Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;62(8):1877-1883.
doi: 10.1080/10428194.2021.1888376. Epub 2021 Feb 22.

Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial

William T Johnson  1 , Saritha Kartan  2 , Kelsey Sokol  2 , Neda Nikbakht  3 , Pierluigi Porcu  2
Affiliations

Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial

William T Johnson et al. Leuk Lymphoma. 2021 Aug.

Abstract

Treatment-specific responses and comprehensive disease characteristics are limited in black patients with cutaneous T-cell lymphoma (CTCL). These shortcomings prompted us to perform a subgroup analysis of black patients enrolled in the MAVORIC trial - an international, randomized, phase 3 trial comparing mogamulizumab vs. vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). Ten percent (N = 37) of the entire MAVORIC population (N = 372) identified as black. Significant clinical differences in black patients when compared to non-black patients included a younger median age at enrollment (53 vs. 66 years; p < 0.001), an increased frequency of MF as opposed to SS (73% vs. 52.8%; p < 0.001), and higher rates of earlier-stage disease (IB-IIA) at enrollment (37.8% vs. 21.2%; p = 0.022). Mogamulizumab offered similar response rates and progression-free survival in black patients (7.57 months) compared to the entire MAVORIC population (7.7 months) and was associated with a similar safety profile.

Keywords: Lymphoma and Hodgkin disease; immunotherapy; lymphoid leukemia.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
A: Investigator-assessed progression-free survival in black patients B: Investigator-assessed progression-free survival in black patients and non-black patients
Figure 1:
Figure 1:
A: Investigator-assessed progression-free survival in black patients B: Investigator-assessed progression-free survival in black patients and non-black patients
Figure 2:
Figure 2:
A: Best global response with mogamulizumab in black patients B: Best global response with vorinostat in black patients
Figure 2:
Figure 2:
A: Best global response with mogamulizumab in black patients B: Best global response with vorinostat in black patients
See this image and copyright information in PMC

References

    1. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Archives of dermatology. 2003;139(7):857–66. - PubMed
    1. Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR. Sezary syndrome: a study of 176 patients at Mayo Clinic. Journal of the American Academy of Dermatology. 2012;67(6):1189–99. - PubMed
    1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143(7):854–9. - PubMed
    1. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73. - PMC - PubMed
    1. Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P. Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chinese clinical oncology. 2019;8(1):10. - PubMed

MeSH terms

LinkOut - more resources